Institutional shares held 177 Million
721K calls
489K puts
Total value of holdings $1.58B
$6.45M calls
$4.37M puts
Market Cap $1.63B
185,944,992 Shares Out.
Institutional ownership 95.23%
# of Institutions 294


Latest Institutional Activity in BCRX

Top Purchases

Q2 2025
Doliver Advisors, LP Shares Held: 274K ($2.4M)
Q2 2025
Versant Capital Management, Inc Shares Held: 154 ($1.35K)
Q1 2025
Millennium Management LLC Shares Held: 3.81M ($33.4M)
Q1 2025
Ubs Group Ag Shares Held: 2.4M ($21.1M)
Q1 2025
Nuveen, LLC Shares Held: 1.42M ($12.5M)

Top Sells

Q1 2025
Avoro Capital Advisors LLC Shares Held: 8.7M ($76.2M)
Q1 2025
Deerfield Management Company, L.P. (Series C) Shares Held: 5.19M ($45.5M)
Q1 2025
Rock Springs Capital Management LP Shares Held: 222K ($1.94M)
Q1 2025
Prudential Financial Inc Shares Held: 589K ($5.16M)
Q1 2025
Panagora Asset Management Inc Shares Held: 530K ($4.64M)

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.


Insider Transactions at BCRX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
980K Shares
From 14 Insiders
Grant, award, or other acquisition 960K shares
Bona fide gift 20K shares
Sell / Disposition
121K Shares
From 7 Insiders
Payment of exercise price or tax liability 94.4K shares
Bona fide gift 20K shares
Open market or private sale 7K shares

Track Institutional and Insider Activities on BCRX

Follow BIOCRYST PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BCRX shares.

Notify only if

Insider Trading

Get notified when an Biocryst Pharmaceuticals Inc insider buys or sells BCRX shares.

Notify only if

News

Receive news related to BIOCRYST PHARMACEUTICALS INC

Track Activities on BCRX